Retatrutide
$149.99
In stockRetatrutide is an investigational peptide engineered to activate GIP, GLP-1, and glucagon receptors and is being studied in advanced clinical programs for cardiometabolic conditions.
| SKU | RC-ST-RETA-20MG |
|---|---|
| Manufacturer | Strandix Peptides |
| Form | Lyophilized Powder |
| Strength | 20 mg |
| Size | 3 mL Vial |
| Reported Result | Supplier spec pending verification |
| Stock | In stock |
| Documentation Status | Pending Final COA |
Retatrutide (LY3437943) is a single investigational molecule designed to engage three nutrient-responsive hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Published phase 2 research evaluated dose-response, safety, and metabolic outcomes in adults with obesity, while phase 3 programs continue to examine obesity, type 2 diabetes, cardiovascular and kidney outcomes, sleep apnea, and related conditions. This compound is presented retatrutide as an investigational compound and should not imply that a research vial is equivalent to a clinical-trial product.
Storage and handling: Follow the manufacturer label and matching batch documentation.
Third-party testing status.
| Batch / Lot | Reported Result | Tested | Partner | Status | Document |
|---|---|---|---|---|---|
| N/A | Supplier spec pending verification | Pending | Pending | Pending Final COA | Pending Final COA |